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Abstract
Aims/hypothesis The aim of this work was to evaluate the
efficacy and safety of canagliflozin vs placebo and sitagliptin
in patients with type 2 diabetes who were being treated with
background metformin.
Methods This randomised, double-blind, four-arm, parallel-
group, Phase 3 study was conducted at 169 centres in 22
countries between April 2010 and August 2012. Participants
(N =1,284) with type 2 diabetes aged ≥18 and ≤80 years who
had inadequate glycaemic control (HbA1c ≥7.0% [53 mmol/
mol] and ≤10.5% [91 mmol/mol]) on metformin therapy
received canagliflozin 100 mg or 300 mg, sitagliptin
100 mg, or placebo (n =368, 367, 366, 183, respectively) for
a 26 week, placebo- and active-controlled period followed by
a 26 week, active-controlled period (placebo group switched
to sitagliptin [placebo/sitagliptin]) and were included in the
modified intent-to-treat analysis set. Randomisation was
performed using a computer-generated schedule; participants,
study centres and the sponsor were blinded to group assign-
ment. The primary endpoint was change from baseline in
HbA1c at week 26; secondary endpoints included changes in
HbA1c (week 52) and fasting plasma glucose (FPG), body
weight, and systolic blood pressure (BP; weeks 26 and 52).
Adverse events (AEs) were recorded throughout the study.
Results At week 26, canagliflozin 100 mg and 300 mg re-
duced HbA1c vs placebo (−0.79%, –0.94%, –0.17%, respec-
tively; p <0.001). At week 52, canagliflozin 100 mg and
300 mg demonstrated non-inferiority, and canagliflozin
300 mg demonstrated statistical superiority, to sitagliptin in
lowering HbA1c (−0.73%, –0.88%,–0.73%, respectively);
differences (95% CI) vs sitagliptin were 0% (−0.12, 0.12)
and −0.15% (−0.27, –0.03), respectively. Canagliflozin
100 mg and 300 mg reduced body weight vs placebo
(week 26: –3.7%, –4.2%, –1.2%, respectively; p <0.001)
and sitagliptin (week 52: –3.8%, –4.2%, –1.3%, respectively;
p <0.001). Both canagliflozin doses reduced FPG and systolic
BP vs placebo (week 26) and sitagliptin (week 52) (p <0.001).
Overall AE and AE-related discontinuation rates were gener-
ally similar across groups, but higher with canagliflozin
100 mg. Genital mycotic infection and osmotic diuresis-
related AE rates were higher with canagliflozin; few led
to discontinuations. Hypoglycaemia incidence was higher
with canagliflozin.
Conclusions/interpretation Canagliflozin improved glycaemia
and reduced body weight vs placebo (week 26) and sitagliptin
(week 52) and was generally well tolerated in patients with type
2 diabetes on metformin.
Clinical trial registry ClinicalTrials.gov NCT01106677
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ANCOVA Analysis of covariance
DPP-4 Dipeptidyl peptidase-4
eGFR Estimated GFR
FPG Fasting plasma glucose
IR Immediate release
LOCF Last observation carried forward
LS Least squares
mITT Modified intent-to-treat
MMTT Mixed-meal tolerance test
PPG Postprandial glucose
SGLT2 Sodium glucose co-transporter 2
SMBG Self-monitored blood glucose
UGE Urinary glucose excretion
UTI Urinary tract infection
XR Extended release
Introduction
Metformin is the recommended first-line pharmacological
therapy for type 2 diabetes but the progressive nature of
the disease often necessitates more intensive treatment
regimens or combination therapy for patients to achieve
and/or maintain glycaemic control [1, 2]. Currently avail-
able antihyperglycaemic agents (AHAs) have distinct risk/
benefit profiles, which must be considered when choosing
an add-on therapy to metformin that meets the needs of each
patient [2, 3]. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a
class of AHAs that are becoming more commonly used as
second agents [2, 4].
Canagliflozin is a sodium glucose co-transporter 2
(SGLT2) inhibitor developed for the treatment of patients
with type 2 diabetes [5–10]. Canagliflozin reduces blood
glucose by lowering the renal threshold for glucose and
increasing urinary glucose excretion (UGE), resulting in a
mild osmotic diuresis and a net caloric loss. In a 12 week
study, canagliflozin significantly improved glycaemic con-
trol and reduced body weight vs placebo in patients with
type 2 diabetes on background metformin, with a low
incidence of hypoglycaemia [5]. Other SGLT2 inhibitors,
dapagliflozin and empagliflozin, have also demonstrated
efficacy in lowering HbA1c and body weight with a low
risk of hypoglycaemia in patients with type 2 diabetes
[11–14]. This 52 week Phase 3 study in patients with
type 2 diabetes inadequately controlled with metformin
monotherapy evaluated the efficacy and safety of
canagliflozin compared with placebo at week 26 and
sitagliptin at week 52.
Methods
Participants and study design
This randomised, double-blind, placebo- and active-
controlled, Phase 3 study (ClinicalTrials.gov NCT01106677)
was conducted at 169 centres in 22 countries. The study
consisted of a 2 week single-blind, placebo run-in period, a
26 week placebo- and active-controlled, double-blind treat-
ment period (period I) followed by a 26 week active-
controlled, double-blind treatment period (period II) and a
4 week follow-up period.
Eligible participants were men and women with type 2
diabetes, aged ≥18 and ≤80 years, who had inadequate
glycaemic control (HbA1c ≥7.0% [53 mmol/mol] and ≤10.5%
[91 mmol/mol]) and who were on stable metformin therapy
(≥2,000 mg/day [or ≥1,500 mg/day if unable to tolerate higher
dose]) for ≥8 weeks and had fasting plasma glucose (FPG)
<15 mmol/l at week−2 and fasting fingerstick glucose
≥6.1 mmol/l and <15 mmol/l on day 1. Participants on metfor-
min immediate-release (IR) monotherapy at protocol-specified
doses at screening directly entered the placebo run-in period.
Those on metformin extended release (XR), metformin IR or
XR at below protocol-specified doses or metformin plus sulfo-
nylurea underwent a metformin IR dose titration/dose stable
and, if applicable, a sulfonylurea washout period of up to
10 weeks, followed by the placebo run-in period.
The following exclusion criteria were applied: repeated
FPG and/or fasting self-monitored blood glucose (SMBG)
≥15.0 mmol/l during the pretreatment phase; history of type
1 diabetes, cardiovascular disease (including myocardial in-
farction, unstable angina, revascularisation procedure or cere-
brovascular accident) in the 3 months before screening or
uncontrolled hypertension; treatment with a peroxisome
proliferator-activated receptor γ agonist, insulin, another
SGLT2 inhibitor or any other AHA (except metformin as
monotherapy or in combination with a sulfonylurea) in the
12 weeks before screening; or estimated glomerular filtration
rate (eGFR) <55 ml min−1 (1.73 m2)−1 (or <60 ml min−1
[1.73 m2]−1 if based upon restriction in local label) or serum
creatinine ≥124 μmol/l (men) or ≥115 μmol/l (women).
The study was conducted in accordance with ethical prin-
ciples that comply with the Declaration of Helsinki and are
consistent with Good Clinical Practices and applicable regu-
latory requirements. The study protocol and amendments
were approved by institutional review boards at participating
institutions. All participants provided written informed con-
sent before taking part in the study.
Randomisation and treatments
During the placebo run-in period, participants received single-
blind placebo capsules matching study drug once daily.
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Participants were randomised to receive canagliflozin 100 mg
or 300 mg, sitagliptin 100 mg or placebo (2:2:2:1) once daily
for 26 weeks. The canagliflozin 100 mg and 300 mg once-
daily doses were selected based on findings from a dose-
ranging, Phase 2 study in patients with type 2 diabetes on
background metformin [5]; a 300 mg twice-daily regimen
provided only incremental benefits vs the once-daily regimen
and was therefore not selected for further development. The
use of placebo as a control for the 26 week core treatment
period was done in accordance with US Food and Drug
Administration and European Medicines Agency regulatory
guidelines [15, 16]. The computer-generated randomisation
schedule was prepared by the sponsor before the study.
Randomisation was balanced using permuted blocks of
seven and stratified by whether a participant was on met-
formin monotherapy or metformin plus sulfonylurea at
screening. After randomisation, HbA1c and FPG values
were masked to the study centres unless they met glycaemic
rescue criteria. After completion of period I, the database
was locked and the study was unblinded by the sponsor
for regulatory filing; the participants and the study centre
and local sponsor personnel remained blinded throughout
period II.
Participants who completed period I then entered period II,
during which those randomised to canagliflozin (100 or
300 mg) or sitagliptin 100 mg continued on those treatments
while those randomised to placebo switched to sitagliptin
100 mg in a blinded fashion. During the double-blind
treatment period, glycaemic rescue therapy with glimepiride
(added to study drug and backgroundmetformin) was initiated
if FPG >15.0 mmol/l after day 1 to week 6, >13.3 mmol/l
after week 6 to week 12, and >11.1 mmol/l after week 12
to week 26. Glimepiride therapy was also started if
HbA1c >8.0% (64 mmol/mol) after week 26.
Endpoints and assessments
The pre-specified primary efficacy endpoint was change in
HbA1c from baseline to week 26; change in HbA1c from
baseline to week 52 was a key, pre-specified secondary end-
point. Other pre-specified secondary endpoints at week 26
were proportion of participants reaching HbA1c <7.0%
(53 mmol/mol), change in FPG, 2 h postprandial glucose
(PPG) and systolic BP and per cent change in body weight,
triacylglycerol (i.e. triglycerides) and HDL-cholesterol. All
participants underwent a mixed-meal tolerance test (MMTT)
on day 1 and at week 26 for assessment of 2 h PPG. Change in
Apo B was assessed in a subset of participants at week 26
based on availability of paired baseline and week 26 archive
samples. Other pre-specified secondary endpoints at week 52
were change in FPG and systolic BP and per cent change in
body weight, triacylglycerol and HDL-cholesterol.
Safety and tolerability were evaluated based on ad-
verse event (AE) reports, safety laboratory tests, vital
sign measurements, physical examinations, SMBG and
12-lead electrocardiograms. AEs pre-specified for addi-
tional data collection included urinary tract infections
(UTIs) and genital mycotic infections. Documented ep-
isodes of hypoglycaemia included biochemically con-
firmed episodes (concurrent fingerstick or plasma glucose
≤3.9 mmol/l) and/or severe episodes (i.e. requiring the assis-
tance of another individual or resulting in seizure or loss of
consciousness).
Statistical analyses
The primary hypothesis was that canagliflozin 300 mg is
statistically superior to placebo in reducing HbA1c from base-
line to week 26. Key secondary hypotheses were statistical
superiority of canagliflozin 100 mg to placebo in HbA1c-
lowering effect at week 26 and non-inferiority of canagliflozin
300 mg or both canagliflozin doses to sitagliptin 100 mg in
reducing HbA1c from baseline to week 52. Primary efficacy
analysis was performed in the modified intent-to-treat (mITT)
population (randomised participants who received ≥1 dose of
study drug) using a last observation carried forward (LOCF)
approach. Assuming a group difference of 0.5% (5.5 mmol/
mol) between canagliflozin and placebo and a common SD of
1.0% (10.9 mmol/mol) for change in HbA1c, and using a
two-sample, two-sided t test with a type I error rate of
0.05, an estimated 86 participants per group were re-
quired to achieve 90% power to demonstrate statistical
superiority of canagliflozin to placebo. To support supe-
riority and non-inferiority objectives for the primary end-
point in the mITT population and for supportive analysis
in the per-protocol population (mITT participants who com-
pleted the study, did not receive rescue therapy and had no
major protocol violations), an estimated 360 randomised par-
ticipants were needed for each active treatment group and 180
for the placebo group, assuming a 35% discontinuation rate
at week 52 and with a 2:2:2:1 randomisation ratio for
canagliflozin 100 mg, canagliflozin 300 mg, sitagliptin 100 mg
and placebo.
Primary efficacy analyses were performed in the mITT
population according to randomised treatment assignment
using LOCF to impute missing data; for participants who
received rescue therapy, the last post-baseline value before
rescue was used. Safety analyses were performed in the same
population according to the predominant treatment received;
in this study, the mITT and safety populations were identical.
Only data from participants randomised to sitagliptin 100 mg
on day 1 (i.e. not including participants who switched from
placebo to sitagliptin at week 26) were included in efficacy
comparisons at week 52. Safety analyses over 52 weeks in-
cluded participants who received canagliflozin 100 mg or
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300 mg or sitagliptin and those who switched from placebo to
sitagliptin after 26 weeks (placebo/sitagliptin group).
An analysis of covariance (ANCOVA) model with treat-
ment and stratification factor as fixed effects and correspond-
ing baseline value as a covariate was used to assess primary
and continuous secondary endpoints. Least squares (LS) mean
differences between groups and two-sided 95% CIs were
estimated. The categorical secondary endpoint was analysed
with a logistic model with treatment and stratification factor as
fixed effects and baseline HbA1c as a covariate. Assessment of
non-inferiority of canagliflozin to sitagliptin was based on a
pre-specified margin of 0.3% for the upper limit of the two-
sided 95% CI for the comparison. If non-inferiority was
demonstrated, then superiority was assessed based on an
upper bound of the 95% CI around the between-group
differences of <0.0%.
Comparisons were performed for canagliflozin vs placebo
at week 26 and vs sitagliptin at week 52 based on pre-
specified hierarchical testing sequences implemented to
strongly control overall type I error due to multiplicity. At
week 26, statistical tests were interpreted at a two-sided sig-
nificance level of 5% for all endpoints except change in
systolic BP, HDL-cholesterol and triacylglycerol. These were
grouped together into two separate families (one each for
canagliflozin 100 mg and 300 mg) and each family was
tested using the Hochberg procedure at the 2.5% signifi-
cance level. Comparisons of canagliflozin with sitagliptin
at week 52 were initiated after statistical superiority of
canagliflozin 100 mg and 300 mg to placebo in HbA1c
lowering at week 26 was established; statistical tests at
week 52 were interpreted at a two-sided significance level
of 5% for all endpoints. The p values are reported for pre-
specified comparisons only.
Results
Participant disposition and baseline characteristics
A total of 1,284 participants were randomised into period I
and received ≥1 dose of study drug (mITT analysis set); of
1,119 participants who completed period I, 1,103 entered
period II and 1,020 completed 52 weeks of treatment
(Fig. 1). The rate of study discontinuation before week 52
was 19.0%, 18.5%, 22.1% and 24.6% with canagliflozin
100 mg, canagliflozin 300 mg, sitagliptin and placebo/
sitagliptin, respectively. Over 52 weeks, the percentage of
participants who received glycaemic rescue therapy was
14.7%, 9.3%, 18.0% and 25.1% with canagliflozin 100 mg,
canagliflozin 300 mg, sitagliptin and placebo/sitagliptin,
respectively (OR [95% CI] with canagliflozin 100 mg
and 300 mg, respectively, of 0.78 [0.53, 1.16] and 0.46
[0.30, 0.72] vs sitagliptin, and 0.51 [0.33, 0.80] and
0.30 [0.19, 0.49] vs placebo/sitagliptin). Demographic
and baseline characteristics were generally similar across
groups (Table 1).
Effect on glycaemic variables
Week 26 (period I only) Atweek 26, canagliflozin 100mg and
300 mg significantly reduced HbA1c from baseline compared
with placebo (difference in LS mean changes of −0.62% and
−0.77% [−6.8 and −8.4 mmol/mol], respectively; p <0.001 for
both); the change in HbA1c with sitagliptin was −0.66%
(−7.2 mmol/mol) relative to placebo (Fig. 2a; electronic sup-
plementary material [ESM] Table 1). Statistical comparison of
canagliflozin with sitagliptin at week 26 was not performed
(not pre-specified). A greater proportion of participants treated
with canagliflozin 100mg and 300 mg achievedHbA1c <7.0%
(53 mmol/mol) than with placebo (45.5%, 57.8% and 29.8%,
respectively; p =0.000 for both); 54.5% of sitagliptin-treated
participants achieved HbA1c <7.0% (53 mmol/mol). Both
canagliflozin doses significantly reduced FPG and 2 h PPG
at week 26 vs placebo (p <0.001 for all; ESM Table 1); FPG
and 2 h PPG were also reduced from baseline with sitagliptin.
Week 52 (periods I and II) At 52 weeks, canagliflozin 100 mg
and 300mg demonstrated non-inferiority to sitagliptin 100mg
in HbA1c-lowering effect (upper limit of the 95% CI less
than pre-specified margin of 0.3%; Fig. 2b, c; Table 2).
Canagliflozin 300 mg demonstrated statistical superiority to
sitagliptin in HbA1c-lowering effect (upper limit of the 95%
CI less than 0.0%). The difference in LS mean changes (95%
CI) for canagliflozin 100 mg and 300 mg vs sitagliptin was
0% (−0.12, 0.12) or 0 mmol/mol (−1.3, 1.3) and −0.15%
(−0.27, –0.03) or −1.6 mmol/mol (−3.0, –0.3), respectively.
The separation in treatment effect between canagliflozin
300 mg and sitagliptin was observed starting at week 6
and continued through week 52. A higher proportion of
participants treated with canagliflozin 300 mg achieved
HbA1c <7.0% (53 mmol/mol) compared with those treated
with canagliflozin 100 mg or sitagliptin (54.7%, 41.4% and
50.6%, respectively; OR [95% CI] of 1.28 [0.92, 1.76]
and 0.66 [0.48, 0.91] with canagliflozin 300 mg and
100 mg vs sitagliptin). The proportion of participants
reaching HbA1c <6.5% (48 mmol/mol) was 26.9%,
21.9% and 24.9% for those treated with canagliflozin
300 mg, canagliflozin 100 mg and sitagliptin, respectively
(OR 1.14 [0.80, 1.62] and 0.84 [0.59, 1.22], respectively).
Over 52 weeks, canagliflozin 100 mg and 300 mg provided
greater reductions in FPG than sitagliptin (difference in LS
mean changes of −0.5 and −1.0 mmol/l, respectively;
p <0.001 for both; Fig. 2d; Table 2), with maximal reductions
at 26 weeks across groups.
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Effect on body weight, BP and lipids
Week 26 (period I only) Atweek 26, canagliflozin 100mg and
300 mg significantly reduced body weight compared with
placebo (p <0.001; ESM Table 1); body weight change was
−1.2% with both sitagliptin and placebo. Both canagliflozin
doses were associated with significant decreases vs placebo in
systolic BP (p <0.001 for both; ESM Table 1). Reductions
from baseline in diastolic BP were also observed with both
canagliflozin doses. Sitagliptin was associated with decreases
from baseline in systolic and diastolic BP.
Both canagliflozin doses significantly increased HDL-
cholesterol compared with placebo at week 26 (p <0.001);
no statistically significant changes in triacylglycerol were seen
with canagliflozin relative to placebo (ESM Table 1). Statisti-
cal testing was not performed (not pre-specified) for other
lipid variables, but 95% CIs for between-group comparisons
in these variables are reported in ESM Table 1. Increases from
baseline in LDL-cholesterol were seen with canagliflozin and
placebo. In a subset of participants with adequate archived
samples for analysis of Apo B (n =586), increases from base-
line of 4.3%, 5.4% and 2.4% were seen with canagliflozin
100 mg and 300 mg and placebo, respectively. Increases from
baseline in triacylglycerol, HDL-cholesterol and LDL-
cholesterol were observed with sitagliptin.
Week 52 (periods I and II) At week 52, canagliflozin 100 mg
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Fig. 1 Study flow diagram.
aAmong 2,883 patients enrolled
and screened, there were 1,599
screen failures (inclusion/
exclusion criteria, n =1,428;
withdrawal of consent, n=115;
other, n =50; adverse event,
n =6). bSome subjects withdrew
from the study after completing
period I and did not enter period
II. CANA, canagliflozin; PBO,
placebo; SITA, sitagliptin
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sitagliptin (Fig. 3, Table 2), with differences in LS mean
per cent changes vs sitagliptin of −2.4% (−2.1 kg) and
−2.9% (−2.5 kg), respectively (p <0.001 for both). Weight
loss occurred most rapidly with canagliflozin up to week 6,
with a continuing, slower decrease followed by an apparent
plateau after week 34. A small, gradual decrease from baseline
was observed with sitagliptin, which also plateaued after
week 34.
Canagliflozin 100 mg and 300 mg significantly decreased
systolic BP relative to sitagliptin at 52 weeks (difference in
LS mean changes of −2.9 and −4.0 mmHg, respectively;
p <0.001 for both; Table 2). The change in diastolic BP from
baseline was −1.8 mmHg with both canagliflozin doses and
−0.3 mmHg with sitagliptin. No notable differences were
observed across groups in changes in pulse rate (−1.3, –1.9
and −1.4 beats/min with canagliflozin 100 mg, canagliflozin
300 mg and sitagliptin, respectively).
At week 52, increases in triacylglycerol from baseline were
seen with both canagliflozin doses, whereas a decrease was
observed with sitagliptin; the difference between canagliflozin
Table 1 Baseline demographics and disease characteristics
Characteristic PBO/SITA (n=183) SITA 100 mg (n =366) CANA 100 mg (n =368) CANA 300 mg (n =367) Total (N =1,284)
Sex, n (%)
Male 94 (51.4) 172 (47.0) 174 (47.3) 165 (45.0) 605 (47.1)
Female 89 (48.6) 194 (53.0) 194 (52.7) 202 (55.0) 679 (52.9)
Age, years 55.3±9.8 55.5±9.6 55.5±9.4 55.3±9.2 55.4±9.4
Race, n (%)
White 129 (70.5) 264 (72.1) 252 (68.5) 256 (69.8) 901 (70.2)
Black or African-American 3 (1.6) 13 (3.6) 16 (4.3) 13 (3.5) 45 (3.5)
Asian 30 (16.4) 41 (11.2) 51 (13.9) 60 (16.3) 182 (14.2)
Othera 21 (11.5) 48 (13.1) 49 (13.3) 38 (10.4) 156 (12.1)
HbA1c, % (mmol/mol) 8.0±0.9 (64±9.8) 7.9±0.9 (63±9.8) 7.9±0.9 (63±9.8) 7.9±0.9 (63±9.8) 7.9±0.9 (63±9.8)
FPG, mmol/l 9.1±2.1 9.4±2.3 9.3±2.3 9.6±2.5 9.4±2.3
Body weight, kg 86.6±22.4 87.7±21.6 88.8±22.2 85.4±20.9 87.2±21.7
BMI, kg/m2 31.1±6.1 32.0±6.1 32.4±6.4 31.4±6.3 31.8±6.2
Duration of diabetes, years 6.8±5.3 6.8±5.2 6.7±5.4 7.1±5.4 6.9±5.3
Data are mean ± SD unless otherwise indicated
a Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple and other
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Fig. 2 Changes in glycaemic
variables (LOCF). (a) Change in
HbA1c at week 26, (b) change in
HbA1c at week 52, (c) mean
HbA1c over time and (d) change
in FPG at week 52. CANA,
canagliflozin; PBO, placebo;
SITA, sitagliptin. Light-grey
triangles, PBO; white diamonds,
SITA 100 mg; dark-grey squares,
CANA 100 mg; black circles,
CANA 300 mg. Error bars show
SE. To convert values for HbA1c
in% into mmol/mol, subtract 2.15
and multiply by 10.929 or use
the conversion calculator at
www.HbA1c.nu/eng/
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Table 2 Summary of efficacy findings at week 52 (LOCF)
Variable SITA 100 mg (n =366) CANA 100 mg (n =368) CANA 300 mg (n =367)
HbA1c, n 354 365 360
Mean ± SD baseline, % (mmol/mol) 7.9±0.9 (63±9.8) 7.9±0.9 (63±9.8) 8.0±0.9 (64±9.8)
LS mean ± SE change, % (mmol/mol) −0.73±0.05 (−8.0±0.5) −0.73±0.05 (−8.0±0.5) −0.88±0.05 (−9.6±0.5)
Difference vs SITA (95% CI), % 0.00 (−0.12, 0.12) −0.15 (−0.27, –0.03)
Difference vs SITA (95% CI), mmol/mol 0.0 (−1.3, 1.3) −1.6 (−3.0, –0.3)
FPG, n 354 365 360
Mean ± SD baseline, mmol/l 9.4±2.3 9.4±2.3 9.6±2.5
LS mean ± SE change −1.0±0.1 −1.5±0.1 −2.0±0.1
Difference vs SITA (95% CI) −0.5 (−0.7, –0.2)a −1.0 (−1.2, –0.7)a
Body weight, n 355 365 360
Mean ± SD baseline, kg 87.6±20.9 88.7±22.3 85.4±20.7
LS mean ± SE change, kg −1.2±0.2 −3.3±0.2 −3.7±0.2
LS mean ± SE per cent change −1.3±0.2 −3.8±0.2 −4.2±0.2
Difference vs SITA (95% CI) −2.4 (−3.0, –1.8)a −2.9 (−3.4, –2.3)a
Systolic BP, n 355 365 360
Mean ± SD baseline, mmHg 128.0±13.5 128.0±12.7 128.7±13.0
LS mean ± SE change −0.7±0.6 −3.5±0.6 −4.7±0.6
Difference vs SITA (95% CI) −2.9 (−4.5, –1.3)a −4.0 (−5.6, –2.4)a
Diastolic BP, n 355 365 360
Mean ± SD baseline, mmHg 77.5±8.0 77.7±8.4 77.9±8.3
LS mean ± SE change −0.3±0.4 −1.8±0.4 −1.8±0.4
Difference vs SITA (95% CI) −1.4 (−2.4, –0.5)b −1.5 (−2.5, –0.5)b
Triacylglycerol, n 339 359 343
Mean ± SD baseline, mmol/l 2.0±1.1 2.2±1.6 2.1±1.5
LS mean ± SE change −0.15±0.05 −0.12±0.05 −0.19±0.05
Median (IQR) per cent change −3.3 (−22.8, 16.7) −2.7 (−28.4, 22.5) −8.7 (−29.1, 23.3)
LS mean ± SE per cent change −0.4±2.5 1.9±2.4 2.8±2.4
Difference vs SITA (95% CI) 2.3 (−3.9, 8.5)c 3.2 (−3.1, 9.5)c
LDL-cholesterol, n 338 358 343
Mean ± SD baseline, mmol/l 2.8±0.9 2.8±0.8 2.8±0.9
LS mean ± SE change 0.08±0.04 0.11±0.04 0.11±0.04
Median (IQR) per cent change 0.9 (−9.6, 16.8) 6.0 (−9.9, 21.8) 5.3 (−8.8, 22.6)
LS mean ± SE per cent change 6.0±1.8 7.7±1.7 8.8±1.8
Difference vs SITA (95% CI) 1.7 (−2.8, 6.2)b 2.8 (−1.8, 7.4)b
HDL-cholesterol, n 338 359 343
Mean ± SD baseline, mmol/l 1.2±0.3 1.2±0.3 1.2±0.3
LS mean ± SE change 0.06±0.01 0.12±0.01 0.14±0.01
Median (IQR) per cent change 4.4 (−4.0, 14.8) 8.0 (0.0, 19.8) 11.1 (0.0, 22.8)
LS mean ± SE per cent change 6.0±1.1 11.2±1.0 13.2±1.1
Difference vs SITA (95% CI) 5.2 (2.5, 7.9)d 7.2 (4.4, 10.0)d
LDL-cholesterol/HDL-cholesterol, n 338 358 343
Mean ± SD baseline, mol/mol 2.6±1.0 2.5±0.9 2.4±0.9
LS mean ± SE change −0.04±0.04 −0.13±0.04 −0.15±0.04
Median (IQR) per cent change −1.7 (−14.1, 14.6) −5.3 (−19.3, 11.7) −4.3 (−18.1, 13.2)
LS mean ± SE per cent change 1.6±1.8 −0.8±1.8 −1.3±1.8
Difference vs SITA (95% CI) −2.4 (−7.1, 2.2)b −2.9 (−7.6, 1.8)b
Non-HDL-cholesterol, n 337 357 340
Mean ± SD baseline, mmol/l 3.7±1.0 3.8±1.1 3.7±1.0
LS mean ± SE change 0.03±0.05 0.04±0.05 0.05±0.05
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and sitagliptin did not reach statistical significance (Table 2).
Median per cent decreases in triacylglycerol were observed
across all groups. Both canagliflozin doses increased HDL-
cholesterol, but statistical comparison of canagliflozin vs
sitagliptin was not performed due to the hierarchical statistical
testing sequence. Statistical testing was not performed (not
pre-specified) for other lipid variables, but 95% CIs for
between-group comparisons in these variables are reported
in Table 2. The 100 mg and 300 mg dosages of canagliflozin
were associated with increases from baseline in LDL-
cholesterol and increases in non-HDL-cholesterol that were
smaller than those in LDL-cholesterol. Decreases from base-
line in the LDL-cholesterol/HDL-cholesterol ratio were ob-
served with both canagliflozin doses, whereas an increase was
seen with sitagliptin.
Safety and tolerability
Overall incidences of AEs and AE-related discontinuations
were generally comparable across groups over 52 weeks, with
slightly higher incidences in the group receiving canagliflozin
100 mg (Table 3). The higher incidence of AE-related discon-
tinuations with canagliflozin 100 mg was not due to an in-
crease in any specific AE. The incidence of AEs related to the
study drug was higher with canagliflozin and sitagliptin than
with placebo/sitagliptin; the incidence of serious AEs was low
and similar across groups. The overall incidence of AEs that
occurred in period II was similar across groups; the incidence
of AEs related to study drug in period II was higher with
canagliflozin and sitagliptin than with placebo/sitagliptin
(ESM Table 2). During period II, the incidence of AEs leading
to discontinuation was higher in the sitagliptin group than in
the other groups, as was the incidence of serious AEs.
Over 52 weeks, canagliflozin was associated with a higher
incidence of genital mycotic infections in men and women.
These were generally mild or moderate in intensity and led to
few discontinuations; most (∼80%) were reported during the
first 26 weeks. The incidence of UTIs was similar across
groups over 52 weeks. A higher incidence of AEs related to
osmotic diuresis (i.e. pollakiuria [increased urine frequency],
polyuria [increased urine volume]) was seen with canagliflozin
vs sitagliptin and placebo/sitagliptin; most were mild in sever-
ity and infrequently led to discontinuation. The incidence of
AEs related to reduced intravascular volume (i.e. postural
dizziness, orthostatic hypotension) was low across groups;
events with canagliflozin were mild to moderate in severity
and none led to discontinuation.
The proportion of participants with documented epi-
sodes of hypoglycaemia over 52 weeks was 6.8% with
both canagliflozin doses, 4.1% with sitagliptin and 2.7%
with placebo/sitagliptin. One participant each receiving
canagliflozin 100 mg and sitagliptin experienced a severe
hypoglycaemic event. During weeks 26–52 (period II),
the incidence of documented hypoglycaemia was similar
with canagliflozin 100 mg and 300 mg and sitagliptin
(4.2%, 5.0% and 4.7%, respectively) and was higher than
with placebo/sitagliptin (1.6%).
Over 52 weeks, decreases in alanine aminotransferase were
observed with canagliflozin, whereas increases were seenwith
sitagliptin and placebo/sitagliptin (Table 4). Canagliflozin was
associated with increased bilirubin, whereas decreases were
seen with sitagliptin and placebo/sitagliptin. Increases in se-
rum creatinine were observed across groups, being of a lower
Table 2 (continued)
Variable SITA 100 mg (n =366) CANA 100 mg (n =368) CANA 300 mg (n =367)
Median (IQR) per cent change 1.9 (−9.7, 13.7) 2.4 (−8.8, 14.8) 2.8 (−8.3, 18.8)
LS mean ± SE per cent change 2.8±1.4 3.8±1.3 4.0±1.4
Difference vs SITA (95% CI) 0.9 (−2.6, 4.4)b 1.1 (−2.4, 4.7)b
a p<0.001 vs SITA
b Statistical comparison vs SITA not performed (not pre-specified)
c p=NS vs SITA
d Statistical comparison vs SITA not performed due to multiplicity control
































Fig. 3 Per cent change in body weight (LOCF). CANA, canagliflozin;
SITA, sitagliptin. White diamonds, SITA 100 mg; dark-grey squares,
CANA 100 mg; black circles, CANA 300 mg. Error bars show SE
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magnitude with canagliflozin than with sitagliptin or placebo/
sitagliptin. All groups showed a reduction in eGFR. This
reduction was observed by week 6 with canagliflozin and
trended back toward baseline over time; eGFR progressively
decreased with sitagliptin through week 18, followed by a
small improvement. An increase in blood urea nitrogen was
seen with canagliflozin vs sitagliptin and placebo/sitagliptin.
Canagliflozin was associated with a decrease in serum urate,
whereas an increase was seen with sitagliptin and placebo/
sitagliptin. An increase in haemoglobin was seen with
canagliflozin, whereas sitagliptin and placebo/sitagliptin were
associated with decreased haemoglobin.
Discussion
Patients with type 2 diabetes often require combination ther-
apies to achieve and/or maintain effective glycaemic control
[1, 2]. In this study of patients with type 2 diabetes on
background metformin, canagliflozin 100 mg and 300 mg
significantly reduced HbA1c from baseline compared with
placebo at week 26 and demonstrated non-inferiority to
sitagliptin 100 mg in HbA1c-lowering effect at week 52;
canagliflozin 300 mg also showed statistical superiority to
sitagliptin in HbA1c-lowering effect. Significant decreases in
FPG, bodyweight and systolic BPwere seenwith canagliflozin
100 mg and 300 mg vs placebo at week 26 and sitagliptin at
week 52, with a sustained effect over 52 weeks. The 100 mg
and 300 mg dosages of canagliflozin were associated with
significant increases in HDL-cholesterol vs placebo at week 26,
with increases from baseline also observed at week 52.
Increases from baseline in LDL-cholesterol were observed
with canagliflozin and sitagliptin, with similar per cent
changes at weeks 26 and 52. The mechanism of LDL-
cholesterol increase with canagliflozin is unknown, but may
reflect downstream metabolic effects of UGE and modest
haemoconcentration resulting from an osmotic diuretic effect
[17]. Increases from baseline in non-HDL-cholesterol, which
were smaller than those in LDL-cholesterol, were seen with
canagliflozin and sitagliptin at weeks 26 and 52.
The safety and tolerability profile of canagliflozin was
consistent with findings from previous Phase 3 studies [6, 8,
9]. Canagliflozin was generally well tolerated, with a pattern
of specific AEs (e.g. genital mycotic infections, osmotic
diuresis-related AEs) that were generally mild or moderate
in severity, occurred at a low incidence and infrequently led to
discontinuation. The incidence of documented hypoglycaemia
was low but was slightly higher with canagliflozin than with
sitagliptin or placebo/sitagliptin. While the incidence of UTIs
was similar with canagliflozin 100 mg and 300 mg and the
control groups (i.e. sitagliptin and placebo/sitagliptin) in the
current study, a small increase in the incidence of UTIs was
observed with canagliflozin 100 mg (5.9%) compared with
canagliflozin 300 mg and placebo (4.3% and 4.0%, respective-
ly) in a pooled analysis across four placebo-controlled Phase 3
studies [18]. The slight imbalance in overall AE incidence with
canagliflozin 100 mg vs 300 mg was primarily driven by early
events during period I; AE rates were more balanced during
period II. In all groups except canagliflozin 300 mg, the inci-
dence of AEs leading to discontinuation increased from
week 26 to week 52; incidences were generally lower during
period II relative to the entire 52 week period.
The results of the current study complement and support
findings from a similar 52 week, Phase 3 study comparing
canagliflozin 300 mg with sitagliptin 100 mg in patients with
type 2 diabetes inadequately controlled with metformin
plus sulfonylurea [8]. In that study, canagliflozin 300 mg
Table 3 Summary of overall safety and selected AEs over 52 weeks












Any AE 122 (66.7) 236 (64.5) 266 (72.3) 230 (62.7)
AEs leading to
discontinuation
8 (4.4) 16 (4.4) 19 (5.2) 12 (3.3)
AEs related to
study druga
23 (12.6) 72 (19.7) 97 (26.4) 73 (19.9)
Serious AEs 7 (3.8) 18 (4.9) 15 (4.1) 12 (3.3)
Deaths 1 (0.5) 1 (0.3) 0 1 (0.3)
Selected AEs
UTI 12 (6.6) 23 (6.3) 29 (7.9) 18 (4.9)
Genital mycotic infection
Menb,c 1 (1.1) 2 (1.2) 9 (5.2) 4 (2.4)
Womend,e 1 (1.1) 5 (2.6) 22 (11.3) 20 (9.9)
Osmotic diuresis-related AEs
Pollakiuriaf 1 (0.5) 2 (0.5) 21 (5.7) 11 (3.0)




1 (0.5) 1 (0.3) 2 (0.5) 2 (0.5)
Orthostatic
hypotension
0 0 0 1 (0.3)
All AEs are reported, regardless of rescue medication
a Possibly, probably or very likely related to study drug, as assessed by
investigators
b PBO/SITA, n=94; SITA 100 mg, n =172; CANA 100 mg, n =174;
CANA 300 mg, n =165
c Including balanitis, balanoposthitis and fungal genital infection
d PBO/SITA, n=89; SITA 100 mg, n =194; CANA 100 mg, n =194;
CANA 300 mg, n =202
e Including vaginal infection, vaginal inflammation, vulvitis, vulvovaginal
candidiasis, vulvovaginal mycotic infection and vulvovaginitis
f Increased urine frequency
g Increased urine volume
CANA, canagliflozin; PBO, placebo; SITA, sitagliptin
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demonstrated non-inferiority and statistical superiority to
sitagliptin in HbA1c-lowering effect at 52 weeks (difference
in LS mean changes of −0.37% [−4.0 mmol/mol]). Greater
reduction in body weight was observed with canagliflozin
relative to sitagliptin (difference of −2.8% [−2.4 kg]);
reductions in FPG and systolic BP were also seen with
canagliflozin vs sitagliptin. Overall AE incidence was similar
with canagliflozin and sitagliptin but the incidence of genital
mycotic infection and osmotic diuresis-related AEs was
higher with canagliflozin. The incidence of hypoglycaemia
was similar with canagliflozin and sitagliptin but was higher
than that observed in the current study, which is likely related
to the additional sulfonylurea treatment in the previous study.
Together with these previous results, the current findings
provide additional evidence supporting the non-inferiority of
canagliflozin 100mg and 300mg, and statistical superiority of
canagliflozin 300 mg, to sitagliptin in HbA1c-lowering effect
in patients with inadequate glycaemic control with their
ongoing AHA therapy. Improvements in glycaemic con-
trol have also been observed with other SGLT2 inhibitors,
and safety findings with canagliflozin in the current study
were generally consistent with those seen with other SGLT2
inhibitors [11–14].
The current study is strengthened by its placebo- and
active-controlled design, allowing for comparison of
canagliflozin with placebo (week 26) and sitagliptin (week 52).
The study population reflects a typical profile of patients with
type 2 diabetes (e.g. broad age range, mostly overweight/
obese, wide range of racial/ethnic groups); thus, study results
should be generalisable to a broad type 2 diabetes population.
This study has several potential limitations. It was designed
with pre-specified comparisons between canagliflozin and
sitagliptin only at week 52, consistent with the assessment
time point commonly used in other active-controlled studies
[8, 19, 20]; therefore, statistical comparisons of canagliflozin
with sitagliptin at week 26 are not reported. Because type 2
diabetes is a chronic disorder, study durations beyond
52 weeks may better define the long-term efficacy and safety
of canagliflozin. Studies comparing canagliflozin with other
AHAs would also be useful for determining the relative
efficacy/safety of canagliflozin as add-on therapy.
In summary, treatment with canagliflozin improved
glycaemic control and reduced body weight compared with
placebo over 26 weeks and with sitagliptin over 52 weeks and
was generally well tolerated in patients whose type 2 diabetes
was inadequately controlled with metformin monotherapy.
Table 4 Summary of clinical













ALT, n 137 282 294 293
Mean baseline, μkat/l 0.5 0.5 0.5 0.5
Mean ± SD per cent change 7.1±40.7 5.1±41.6 −2.2±39.9 −10.2±39.6
AST, n 137 281 292 293
Mean baseline, μkat/l 0.4 0.4 0.4 0.4
Mean ± SD per cent change 9.8±31.8 7.1±36.8 2.6±32.6 −2.4±28.9
Bilirubin, n 138 282 296 293
Mean baseline, μmol/l 9.1 8.7 9.0 8.5
Mean ± SD per cent change −3.9±31.4 −1.3±33.4 11.6±45.6 14.3±41.1
BUN, n 139 282 296 295
Mean baseline, mmol/l 5.4 5.5 5.1 5.2
Mean ± SD per cent change 5.9±33.8 3.5±26.6 14.8±26.7 16.1±33.4
Creatinine, n 139 282 296 295
Mean baseline, μmol/l 73.9 72.0 71.4 70.2
Mean ± SD per cent change 3.3±18.0 3.4±13.6 2.3±11.4 2.5±12.4
eGFR, n 139 282 296 295
Mean baseline, ml min−1 (1.73 m2)−1 87.7 89.1 89.7 90.2
Mean ± SD per cent change −1.4±18.2 −2.4±12.8 −1.4±12.8 −1.5±12.9
Urate, n 139 282 296 295
Mean baseline, μmol/l 333.4 328.8 316.6 311.2
Mean ± SD per cent change 5.0±17.4 3.9±18.4 −10.5±18.3 −11.0±18.8
Haemoglobin, n 134 277 292 285
Mean baseline, g/l 141.3 141.0 140.5 140.0
Mean ± SD per cent change −1.6±6.0 −1.6±6.2 4.0±7.2 3.7±7.1
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These findings support the clinical usefulness of canagliflozin
as add-on therapy in patients with type 2 diabetes.
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